CancerDrs

Colorectal Cancer clinical trials in Rhode Island

9 actively recruiting colorectal cancer trials at 2 sites across Rhode Island.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Rhode Island:
  • Roger Williams Medical Center — Providence, Rhode Island
  • Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 1, Phase 2 Recruiting Industry

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…

Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Rhode Island:
  • Brown University Health Cancer Institute — Providence, Rhode Island
Phase 2 Recruiting Academic/Other

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have be…

Sponsor: Brown University
NCT ID: NCT06555133
Sites in Rhode Island:
  • Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact: — Providence, Rhode Island
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…

Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Miriam Hospital — Providence, Rhode Island
Phase 1 Recruiting Industry

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…

Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
Phase 1 Recruiting NIH

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polypo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05630794
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Rhode Island:
  • Providence Veterans Administration Hospital — Providence, Rhode Island
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Rhode Island:
  • Massive Bio SYNERGY-AI site — Providence, Rhode Island

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25